MiyauchiA, TakamuraY, ItoY, MiyaA, KobayashiK, MatsuzukaF, AminoN, ToyodaN, NomuraE, NishikawaM. 2008. 3,5,3′-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab, 93:2239–2242.
2.
SchlumbergerM, TaharaM, WirthLJ, RobinsonB, BroseMS, EliseiR, HabraMA, NewboldK, ShahMH, HoffAO, GianoukakisAG, KiyotaN, TaylorMH, KimSB, KrzyzanowskaMK, DutcusCE, de las HerasB, ZhuJ, ShermanSI. 2015. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med, 372:621–630.
3.
BiancoAC, SalvatoreD, GerebenB, BerryMJ, LarsenPR. 2002. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev, 23:38–89.
4.
KappersMH, van EschJH, SmedtsFM, de KrijgerRR, EechouteK, MathijssenRH, SleijferS, LeijtenF, DanserAH, van den MeirackerAH, VisserTJ. 2011. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab, 96:3087–3094.
